期刊文献+

早期类风湿性关节炎患者血清Ⅰ型胶原吡啶交联终肽、基质金属酶-3等指标的检测及意义 被引量:8

Detection and significance of serum cross-linked carboxyterminal telopeptide region of type Ⅰ collagen and matrix metalloproteinase enzyme-3 in patients with early rheumatoid arthritis
下载PDF
导出
摘要 目的探讨Ⅰ型胶原吡啶交联终肽(ICTP)、基质金属酶-3(MMP-3)、抗环瓜氨酸肽(CCP)抗体、类风湿因子(RF)检测及类风湿性关节炎(RA)活动度在RA早期诊断中的意义。方法应用酶联免疫吸附试验(ELISA)检测213例RA患者(早期RA组92例、中长期RA组121例)、43例非RA的其他免疫系统疾病患者和40名正常对照者血清ICTP、MMP-3及抗CCP抗体;同时采用免疫比浊法检测血清RF。结果 ICTP、MMP-3、抗-CCP抗体、RF在早期RA诊断中的最佳临界值分别为3.21μg/L、67.45 ng/mL、15.45 U/mL、12.35 U/mL,灵敏度分别为74.0%、63.4%、52.4%、55.3%,特异性为95.5%、81.8%、95.5%、90.9%。RA各组RF、抗CCP水平均高于对照组及非RA组(P<0.01),ICTP、MMP-3、RF在非RA组和正常对照组间差异有统计学意义(P<0.01),ICTP在早期RA与非RA组间差异无统计学意义(P>0.05)。X线分期中Ⅰ期患者的ICTP、MMP-3、抗CCP抗体及RF水平与Ⅱ、Ⅲ期、Ⅳ期患者比较差异均有统计学意义(P<0.05、P<0.01)。Ⅱ期患者ICTP、MMP-3及抗CCP抗体水平与Ⅲ、Ⅳ期比较差异均有统计学意义(P<0.05、P<0.01),而RF水平3组之间差异无统计学意义(P>0.05)。结论同时检测ICTP、MMP-3、抗CCP抗体和RF能提高RA早期诊断的准确性,减少漏诊,动态联合检测可有效监测RA病情进展。 Objective To investigate the significance of cross-linked carboxyterminal telopeptide region of type Ⅰ collagen (ICTP), matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibody, rheumatoid factor (RF) and rheumatoid arthritis (RA) activity in the early diagnosis of RA. Methods The enzyme-linked immunosorbent assay(ELISA) was used to determine the serum samples of 213 patients with RA (early RA group: 92 cases and medium-and long-term RA group: 121 cases) , 43 patients with non-RA associated and immune diseases and 40 healthy controls. The serum ICTP, MMP-3 and anti-CCP antibody were determined. The serum RF was determined by immunoturbidimetry. Results The optimal cut-off values of ICTP, MMP-3 and anti-CCP antibody in the diagnosis of early RA were 3.21 μg/L, 67.45 ng/mL, 15.45 U/mL and 12.35 U/mL. The sensitivities were 74.0% ,63.4%, 52.4% and 55.3%, and the specificities were 95.5%, 81.8%, 95.5% and 90.9%. RF and anti-CCP antibody were higher in the RA group than in the healthy control group and the non-RA group ( P 〈 0.01 ). ICTP, MMP-3 and RF in the non-RA group and the healthy control group had statistical significance ( P 〈0.01 ). ICTP in early RA and non-RA group had no statistical significance (P 〉 0.05). The ICTP, MMP-3, anti-CCP antibody and RF of X ray staging Phase I had statistical significanees with those staging Phase Ⅱ , Ⅲand Ⅳ ( P 〈 0.05, P 〈 0. 01 ). The ICTP, MMP-3 and anti-CCP antibody of Phase Ⅱwith those of Phase Ⅲ and Ⅳ had statistical significance ( P 〈 0.05, P 〈 0.01 ). The RF among Phase Ⅱ ,Ⅲ and Ⅳ had no statistical significance ( P 〉 0.05 ). Conclusions The simultaneous detection of ICTP, MMP-3, anti-CCP antibody and RF can improve accuracy and reduce missed diagnosis. Dynamic combination detection can monitor effectively the progression of RA.
出处 《检验医学》 CAS 2013年第5期400-403,共4页 Laboratory Medicine
基金 嘉兴市科技局计划项目(2010AY1053)
关键词 Ⅰ型胶原吡啶交联终肽 基质金属酶 3 抗环瓜氨酸肽抗体 类风湿因子 类风湿性关节炎 Cross-linked carboxyterminal telopeptide region of type I collagen Matrix metalloproteinase-3 Anti-cyclic citrullinated peptide antibody Rheumatoid factor Rheumatoid arthritis
  • 相关文献

参考文献13

  • 1Bas S, Perneger TV, Seitz M, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide anti-bodies, anti-keratin anti- bodies and IgM rheumatoid factor[ J ]. Rheumatology (Oxford) ,2002,41 (7) :809-814.
  • 2Bukhari M, Harrison B, Lunt M, et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study[ J]. Arthritis Rheum, 2001, 44(6) : 1248-1253.
  • 3Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide [ J ]. Arthritis Rheum ,2000,43 ( 1 ) : 155-163.
  • 4Stenman M, Ainola M, Valmu L, et al. Trypsin-2degrades human type Ⅱ collagen and is expressed and activated in mesenchymally transformed rheu- matoid arthritis synovitis tissue [ J ] . Am J Pathol, 2005,167 (4) : 1119-1124.
  • 5Maskos K, Bode W. Structural basis of matrix metallo- proteinases and tissue inhibitors of metalloproteinases [J]. Mol Biotechnol, 2003,25(3) :241-266.
  • 6Breyholz I-IJ, Wagner S, Levkau B, et al. A 18F- radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo [ J ]. Q J Nucl Med Mol Imaging, 2007,51 ( 1 ) :24-32.
  • 7Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthri- tis[ J]. Arthritis Rheum, 2000,43 (4) :852-858.
  • 8Kamphuis S, I-Irafnkelsd6ttir K, Klein MR, et al. Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive distinct auto- reactive T-cell responses in juvenile idiopathic arthri- tis and in health [ J ]. Arthritis Res Ther, 2006, 8 (6) :R178.
  • 9Kiuchi K, Ishikawa T, Hamaguchi Y, et al. Cross- linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer [ J ]. Oncol Rep, 2002,9(3) :595-598.
  • 10Chung YC, Ku CH, Chao TY, et al. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment [ J ]. Cancer Epidemiol Bio- markers Prey, 2006,15 ( 3 ) :424-428.

同被引文献74

  • 1张义浜,刘志敏,熊凌霜.类风湿关节炎发病机制及其治疗方法研究进展[J].细胞与分子免疫学杂志,2005,21(B03):88-90. 被引量:65
  • 2Hakala M, Risteli J,Aman S, et al. Combination druystrategy in recent-onset rheumatoid arhritis suppressescollagen I degradation and is associated withretardation of radiological progression [ J ]. Scand JRheumatol,2008,37(2) :90-93.
  • 3Ruderman E M. Current and future pharmaceutical therapy for rheumatoid arthritis [J]. Current pharmaceutical design, 2005, 11(5): 671-684.
  • 4Hider S L, Buckley C, Silman A J, et al. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis [J]. J. Rheumatol, 2005, 32(1): 11-16.
  • 5Barnett M L, Combitchi D, Trentham D E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis [J]. Arthritis & Rheumatism, 1996, 39(4): 623-628.
  • 6Schellekens GA, Visser H, De-Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies reocognizing a cyclic citrullinated peptide [J]. Arthritis Rheum, 2000, 43: 155-163.
  • 7Cook A D, Rowley M J, Mackay I R, et al. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression [J]. Arthritis & Rheumatism, 1996, 39(10) 1720-1727.
  • 8Yang L, Anderson D E, Baecher-Allan C, et al. IL-21 and TGF-beta are requiredfor differentiation of human T (H) 17 cells [J]. Nature, 2008, 454:350-352.
  • 9Manel N, Unutmaz D, Littman D R. Thedifferentiation of humanT(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor gammar [J]. Nat Immtmol, 2008, 9:641-649.
  • 10Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interliulin-1 receptor antagonist [J]. Semin Arthritis Rheum 2001, 30(Suppl 2): 1-6.

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部